Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis

Abstract

BackgroundIn recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. Although several studies have been published, no bibliometric analysis have been conducted on this topic.ObjectivesTo understand the development status and future trends in the application of HAIC, we conducted bibliometric analysis to examine the cooperation and influence among countries, institutions, authors, and journals.MethodsAll relevant articles and reviews on the use of HAIC in HCC treatment were retrieved from the Web of Science database. A bibliometric analysis of countries, institutions, journals, authors, and keywords related to this field was performed using R and VOSviewer software. The main aspects analyzed were the research status and key fields of HAIC in HCC treatment.ResultsA total of 1026 articles published in 292 journals by 4937 authors from 959 institutions between 1974 and 2021 were retrieved. A rapid increase in articles published after 1990 was observed, which reached the peak in 2021. Japan had the most publications and citations. Yonsei University, Sun Yat-sen University, and Hiroshima University were the three leading institutions in research on this topic. Kwang-Hyub Han and Masatoshi Kudo have the greatest academic influence in this field. Most publications were made in the Hepato-Gastroenterology, whereas cancer had the most citations. The main aspects of HAIC treatment of HCC include HAIC and TACE, chemotherapy drug selection, HAIC and targeted therapy and immunotherapy, HAIC and surgery, and hepatotoxicity. Keywords such as FOLFOX, lenvatinib, hepatic arterial infusion chemotherapy are hot words in this field in recent years.ConclusionThe research on the use of HAIC in the treatment of HCC has been on the rise. Currently, HAIC combined with targeted therapy or immunotherapy has attracted significant attention.

A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy

“…The characteristics include successful surgical conversion, receipt of systemic therapy before combined treatment, the presence of hypertension, diabetes, heart disease, smoking history, alcohol consumption history, the presence of inferior vena cava tumor thrombus, and the presence of portal vein tumor thrombus. Currently, the recommended initial therapy for advanced liver cancer involves administering a blend of molecular targeted drugs and ICI (25,26). Targeted therapy combined with immunotherapy, as the mainstream treatment, has achieved a good local control rate and survival benefits in patients with advanced liver cancer; however, the ORR and OS remain unsatisfactory.…”

“…Currently, the recommended initial therapy for advanced liver cancer involves administering a blend of molecular targeted drugs and ICI ( 25 , 26 ). Targeted therapy combined with immunotherapy, as the mainstream treatment, has achieved a good local control rate and survival benefits in patients with advanced liver cancer; however, the ORR and OS remain unsatisfactory.…”